Navigation Links
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Date:12/8/2009

SAN DIEGO, Dec. 8, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET / 10:35 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

SOURCE Amylin Pharmaceuticals, Inc.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
2. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
3. Amylin Pharmaceuticals Reports Second Quarter Financial Results
4. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
5. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
6. Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today
7. Three Independent Proxy Advisory Firms Support Stockholder Nominees in Amylin Proxy Fight
8. Amylin Issues Statement Regarding Open Letter From Icahn
9. Icahn Issues Open Letter to Amylin Shareholders
10. Amylin Sends Letter to Shareholders
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology: